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Efficacy of adjuvant or neoadjuvant chemotherapy with surgical 
resection of stage lB-llB Non-small-cell lung cancer
Lee, Jeong Eun; Joung, Mi-Kyong; Lee, Yu-Jin; Park, Hee-Sun; Jung, 
Sung-Soo; Kim, Ju-Ock; Kim, Sun-Young 
Department of Internal Medicine, Chungnam National University Hos-
pital & Cancer Research Institute, Dae-jeon, Korea
Background: The therapeutic efﬁcacy of adjuvant or neoadjuvant 
chemotherapy with surgical resection of stage lB-llB non-small-cell 
lung cancer (NSCLC) has been less clear. We performed a retrospec-
tive study of adjuvant or neoadjuvant chemotherapy with vinorelbine 
plus cisplatin or etoposide plus cisplatin to validate the efﬁcacy on the 
patients with early stage NSCLC. Response, survival data and the feasi-
bility of chemotherapy were analyzed. 
Methods: 48 patients diagnosed as stage IB - IIB NSCLC from Janu-
ary 1994 to February 2006, were enrolled for analysis. All patients re-
ceived either 30 mg/m2 vinorelbine plus 100 mg/m2 cisplatin (n=17) or 
100 mg/m2 etoposide plus 100 mg/m2 cisplatin (n=31) every 3 weeks, 
before operation or after operation. In neoadjuvant setting, after 3 
cycles of chemotherapy, restaging was done with chest CT, followed by 
surgery. Postoperative radiotherapy was at the investigator’s discretion. 
Results: 10 patients (20.8%) had stage lB disease and 38 patients 
(79.2%) had stage llB disease. The adjuvant chemotherapy group 
was 22(45.8%) patients and neoadjuvant chemotherapy group was 26 
(54.2%) patients. The median duration of follow-up was 45.5 (6-187) 
months. The median survival was 46 (6-187) months and disease-free 
survival was 31 (5-187)months. The overall survival of patients who 
adjuvant chemotherapy was similar compared with the patients who 
neoadjuvant chemotherapy (46 vs 46 months, p=0.125). The overall 
survival of patients of stage lB patients was more prolonged than that 
of stage llB patients (51 vs 46 months, p=0.048). The Grade 3/4 he-
matologic toxicities of chemotherapy were neutropenia (n=9), anemia 
(n=1), and thrombocytopenia (n=1). 
Conclusion: The adjuvant or neoadjuvant choemotherapy of vinorel-
bine plus cisplatin or etoposide plus cisplatin has an acceptable level 
of toxicity and may prolong overall survival among patients with 
completely resected stage lB-llB NSCLC.
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Weekly Low-dose Docetaxel for Pretreated Elderly or Less Fit 
Patients with Non-small Cell Lung Cancer
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Background: Second-line single-agent docetaxel showed superiority in 
overall survival compared with best supportive care alone in previously 
treated patients with non-small cell lung cancer (NSCLC). However, 
for elderly or less ﬁt patients, chemotherapy is associated with greater 
toxicity and less beneﬁt, and the efﬁcacy of salvage docetaxel chemo-
therapy for these patients is still controversial. Therefore, we evaluated 
the efﬁcacy and toxicity proﬁles of weekly low-dose docetaxel regimen 
administered in daily clinical practice for elderly or less ﬁt NSCLC 
patients previously exposed to chemotherapy. 
Methods: Between May 2004 and January 2007, forty unselected, 
consecutive and prospectively enrolled patients with stage IIIB or IV 
NSCLC, previously treated with one or more chemotherapy regimens, 
received docetaxel as single-agent salvage chemotherapy at Seoul Na-
tional University Bundang Hospital. All patients were aged ≥ 65 years, 
or had an ECOG performance status of ≥ grade 2 in the cases of ages < 
65 years. Docetaxel was administered at a dose of 25 mg/m2 weekly on 
days 1, 8, and 15 of a 28-day cycle in an outpatient setting. 
Results: Median age was 66 years (range 38 to 80). Twenty-nine 
patients (73%) received docetaxel as second-line chemotherapy and 
eleven (28%) as third- or fourth-line treatments. Platinum, gemcitabine, 
paclitaxel, epidermal growth factor (EGFR) inhibitors were previously 
employed in 39 (98%), 37 (93%), 9 (23%) and 9 patients (23%), re-
spectively. A median of 2 cycles (range 1 to 6) were administered and, 
of 40 patients enrolled, nine patients (23%) showed partial responses. 
Nine patients (23%) showed stable disease and 17 (43%) progressive 
disease. Five patients (13%) were not evaluable. Grade 3/4 toxicities 
were rare: asthenia in 8% of patients, anorexia in 8%, mucositis in 5%, 
diarrhea in 3%, neutropenia in 3%, nail change in 3%, and peripheral 
neuropathy in 3%. Drug toxicity was the reason for the treatment 
discontinuation in 5 patients (13%). At median follow-up of 18 weeks, 
22 patients are alive. Median progression-free survival and overall sur-
vival were 9.9 weeks (95% conﬁdence interval [CI]: 7.1~12.7 weeks) 
and 37.7 weeks (95% CI: 21.0~54.3 weeks), respectively.
Conclusions: Weekly low-dose docetaxel appears to be well toler-
ated as salvage chemotherapy for previously treated elderly or less ﬁt 
patients with NSCLC. The efﬁcacy of this low-dose regimen seems to 
be comparable to the standard 3-week or higher-dose weekly docetaxel 
regimens. This approach provides a reasonable alternative for pretreat-
ed elderly or less ﬁt patients with NSCLC. 
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Background: Lung cancer is the most common cause of cancer death 
throughout the world. Chemotherapy is a main treatment modality but 
resistance to treat is a major problem in non-small cell lung cancer 
(NSCLC). Neoplastic transformation involves events that inhibit the 
program of senescence, and tumor cells were believed until recently to 
have lost the ability to senesce. As chemotherapeutic drugs can induce 
tumor cells to senesce, the aim of the present study was to investigate 
correlation between the clinical response of taxanes plus cisplatin 
combination chemotherapy and combination of docetaxel and cisplatin 
(DC) induced senescence in vitro, the contribution of m-P53 protein re-
leasing in tumor cells, and whether DC induced senescence assay could 
have clinical implications as a chemsensitivity indicator in vivo.
Methods: Sixty-seven specimen obtained from NSCLC patients from 
Jan 1, 2003 to Jun 30, 2006. The patients consisted of 48 males and 
19 females, ranging in age from 54 to 82 years (mean, 67.5 years), 41 
cases were diagnosed as pathological stage IIIb, 26 cases were diag-
nosed as stage IV. Thirty-nine tumors were conﬁrmed to be adenocarci-
nomas, 28 were conﬁrmed to be squamous cell carcinomas. All patients 
accept 2-6 cycles combination chemotherapy of Taxanes (docetaxel 
